Suppression of inflammasome activation

1 . A method for suppressing inflammasome activation in a subject in need thereof, the method comprising administering to a subject a therapeutically effective amount of a compound of Formula (I), or a salt thereof:

wherein

R 1 is C 1 -C 6 alkyl;

R 2 is cyclopentyl;

R 3 is -Y-C(O)R 4 ;

R 4 is —OR 7 ;

X 1 and X 2 are each independently alkyl or halo,

is hydrogen or alkyl;

Y is

and

n is 1 or 2.

2 . The method of claim 1 wherein Y is selected from the group consisting of

3 . The method of claim 1 wherein R 3 is selected from the group consisting of:

4 . The method of claim 1 wherein X 1 and X 2 are each independently selected from C 1 to C 6 alkyl, fluoro, chloro, bromo, or iodo.

5 . A method for suppressing inflammasome activation in a subject in need thereof, the method comprising administering to a subject a therapeutically effective amount of a compound, or a salt thereof selected from the group consisting of:

6 . The method of claim 1 wherein the subject has an inflammatory disease selected from the group consisting of a rheumatologic and connective tissue disease, a systemic vasculitide, sarcoidosis, a dermatologic inflammatory disease, sepsis/systemic inflammatory response syndrome, and acute respiratory distress syndrome.

7 . The method of claim 1 wherein the subject has an inflammatory disease selected from atherosclerosis, pericarditis, and myocarditis.

8 . The method of claim 1 wherein the subject has an inflammatory disease selected from ulcerative colitis, Crohn's disease, nonalcoholic inflammatory bowel steatohepatitis, fibrosis, alcoholic hepatitis, and autoimmune hepatitis.

9 . The method of claim 1 wherein the subject has an inflammatory disease selected from glomerulonephritis, interstitial nephritis, anti-tubular basement membrane antibody-mediated tubulointerstitial nephritis, IgG4-related disease, asthma, bronchitis, and pulmonary interstitial fibrosis, pneumonitis, familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome (TRAPS), familial cold auto-inflammatory syndrome, Muckle-Wells syndrome, Schnitzler syndrome, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, Parkinson's disease, Guillain-Barre syndrome, multiple sclerosis, and idiopathic transverse myelitis.

10 . The method of claim 1 , wherein R 1 is butyl.

11 . The method of claim 1 , wherein X 1 and X 2 are each independently methyl, fluoro, or chloro.